5589-61-7

Usage

Uses

Used in Pharmaceutical Industry:
2-(butylamino)benzonitrile is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with specific therapeutic properties. Its structural features allow for the creation of molecules with targeted biological activities.
Used in Agrochemical Industry:
In the agrochemical sector, 2-(butylamino)benzonitrile serves as an intermediate in the production of various agrochemicals, including pesticides and herbicides, due to its potential to enhance the effectiveness and selectivity of these compounds in agricultural applications.
Used in Dye Industry:
2-(butylamino)benzonitrile is utilized as a building block in the synthesis of dyes, where its chemical structure contributes to the color and stability of the final dye products, catering to the needs of different industries such as textiles and printing.
Used in Organic Electronic Devices:
2-(butylamino)benzonitrile has been studied for its potential use in organic electronic devices, such as organic light-emitting diodes (OLEDs) and organic solar cells, owing to its electronic properties that can influence the performance of these devices.
Used in Material Science:
As a building block for the production of novel materials, 2-(butylamino)benzonitrile is employed in material science for its potential to create new compounds with unique properties, such as improved conductivity or specific optical characteristics, expanding the horizons of material development.

Upstream product

• 394-47-8 2-fluorobenzonitrile 
• 109-73-9 N-butylamine 
• 873-32-5 2-Chlorobenzonitrile 
• 4426-47-5 butylboronic acid 
• 612-24-8 o-nitrobenzonitrile 
• 25413-69-8 N-butyl-N-nitroso-aniline 
• 55305-43-6 N-cyano-N-phenyl-p-toluenesulfonamide 

Relevant academic research and scientific papers

Aryl-Diadamantyl Phosphine Ligands in Palladium-Catalyzed Cross-Coupling Reactions: Synthesis, Structural Analysis, and Application

Synthesis, temperature-dependent NMR structure investigation and utilization of a new, stable and easily accessible aryl-diadamantylphosphine ligand family is reported. The bulky and electron-rich phosphorus center of the ligand enhances the catalytic activity of palladium in cross-coupling reactions of sterically demanding ortho-substituted aryl halides. In our study, we demonstrated the synthetic applicability of the new phosphine ligands in Buchwald-Hartwig and tosyl hydrazone coupling reactions.

Reductive Molybdenum-Catalyzed Direct Amination of Boronic Acids with Nitro Compounds

The synthesis of aromatic amines is of utmost importance in a wide range of chemical contexts. We report a direct amination of boronic acids with nitro compounds to yield (hetero)aryl amines. The novel combination of a dioxomolybdenum(VI) catalyst and triphenylphosphine as inexpensive reductant has revealed to be decisive to achieve this new C?N coupling. Our methodology has proven to be scalable, air and moisture tolerant, highly chemoselective and engages both aliphatic and aromatic nitro compounds. Moreover, this general and step-economical synthesis of aromatic secondary amines showcases orthogonality to other aromatic amine syntheses as it tolerates aryl halides and carbonyl compounds.

Rhodium(III)-Catalyzed Direct Cyanation of Aromatic C-H Bond to Form 2-(Alkylamino)benzonitriles Using N-Nitroso As Directing Group

2-(Alkylamino)benzonitriles were synthesized via a rhodium-catalyzed cyanation on the aryl C-H bond and subsequent denitrosation of N-nitrosoarylamines using a removable nitroso as the directing group, in which N-cyano-N-phenyl-p-methylbenzenesulfonamide (NCTS) was used as the "CN" source. Various substituents on the aryl ring and amino group of N-nitrosoarylamines tolerated the reaction, and the corresponding products were achieved in moderate to good yields.

Method of inhibiting neoplastic cells with imidazoquinazoline derivatives

A method for inhibiting neoplasia, particularly cancerous and precancerous lesions by exposing the affected cells to imidazoquinazoline derivatives.

Imidazoquinazoline derivatives

PCT No. PCT/JP97/03023 Sec. 371 Date Apr. 27, 1998 Sec. 102(e) Date Apr. 27, 1998 PCT Filed Aug. 29, 1997 PCT Pub. No. WO98/08848 PCT Pub. Date Mar. 5, 1998Imidazoquinoline derivatives of the formula (wherein X may be O or S) provide selective cyclic guanosine 3',5' monophosphate (cGMP)-specific phosphodiesterase (PDE) inhibitory activity. The compounds are useful for treating or ameliorating cardiovascular disease such as thrombosis, angina pectoris, hypertension, heart failure and arterial sclerosis, as well as asthma, impotence and the like.